Puma Biotechnology | PBYI - Выручка от реализации





Продажи Изменить Дата
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amgen USD 8.62B 1.28B 2026-03
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Daiichi Sankyo JPY 587B 28.89B 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Exelixis USD 610.8M 12.14M 2026-03
Gilead Sciences USD 7B 930M 2026-03
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.27B 240M 2026-03
MacroGenics USD 20.8M 20.43M 2026-03
Moderna USD 389M 289M 2026-03
Novartis USD 13.11B 226M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Takeda JPY 1.09T 100B 2026-03
TG Therapeutics USD 194.8M 2.23M 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 2.99B 200M 2026-03